SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced the Genome AnalyzerIIe sequencing system, designed to provide a lower-priced entry point into next-generation sequencing. Priced at $250,000 USD, the new system leverages the architecture of Illumina’s widely-adopted Genome AnalyzerIIx and its proven sequencing-by-synthesis chemistry to generate approximately 200 million paired-end reads and 20 gigabases (Gb) of data per run at launch. As Illumina introduces advances to increase the output of the Genome AnalyzerIIx to 95 Gb, the output of the Genome AnalyzerIIe is expected to reach 40 Gb and 300 million paired-end reads per run. The system’s compelling price point coupled with its ease of use and proven sequencing technology ideally positions it for smaller laboratories interested in next-generation sequencing.
